Protara Therapeutics Inc (TARA) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Protara Therapeutics Inc stock $2.11, price $2.30, that is 8.3% below the price, quality 31 out of 100. Rating: fairly valued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.
Show moreShow less
The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Stock analysis
Protara Therapeutics Inc (TARA) currently trades at $2.30, while our model-based Fair Value estimate is $2.11, so the stock looks roughly fairly valued today (gap 9.1%).
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $1.39 (bear) to $2.64 (bull), the price of $2.30 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Protara Therapeutics Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$57.4M in FY2025.
Key figures
Market cap $140M Micro · EPS (TTM) $−1.37 · Return on equity −45.8% · Return on assets (EBIT) −40.0% (5-year average) · Free cash flow −$56.5M · Net cash $46.3M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).
What moves the price
The share trades about 70% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −8%, TARA screens richer than that median.
Fair Value models
Bear$1.39Fair Value $2.11Bull$2.64
Price $2.30 · Downside -8.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham)$1.64$2.48$3.1052
All 1 models by family
Asset-Based
NCAV (Graham)$1.64$2.48$3.1052
The fair value above starts from this blend and is adjusted for dilution from new shares.
In the last 6 months, one officer or director sold shares worth $882,160 and none bought.
SaleJesse SheffermanCEO and President, Director215,687 shares at $4.09$882,160Jun 29, 2026
SaleJacqueline ZummoChief R&D Officer2× since Apr 1, 2026: 23,732 shares, avg. $5.27$124,989Apr 8, 202610b5-1 plan
Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Protara Therapeutics Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score31 · Bottom 25%
Fair Value upside−8.3% · Above median
Profitability
Return on assets−27.4% · Below median
Operating margin (12 months)0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY)0.0% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Protara Therapeutics Inc (TARA) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $2.11 versus a price of $2.30, about 8% lower (fairly valued).
What is the fair value of TARA?
Our model-based fair value for Protara Therapeutics Inc is $2.11 (as of Nov 6, 2026), built from audited fundamentals. The current price: $2.30.
What is the quality score of TARA?
Protara Therapeutics Inc has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Protara Therapeutics Inc (TARA)?
Our model-based price target is the fair value of $2.11 (as of Nov 6, 2026) from 1 valuation models. Cautious scenario $1.39, optimistic scenario $2.64. It is a calculation from audited fundamentals, not an analyst target.
What is the Protara Therapeutics Inc stock forecast for 2026?
Our models put fair value at $2.11, about 8% lower versus a price of $2.30 (fairly valued). Cautious scenario $1.39, optimistic scenario $2.64. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Protara Therapeutics Inc (TARA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Protara Therapeutics Inc it is $2.11 per share (as of Nov 6, 2026), against a price of $2.30. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Protara Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, TARA trades above its calculated fair value: price $2.30, fair value $2.11, a gap of about −8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TARA?
No. The price is what the market pays today ($2.30); the fair value is what the company's own numbers justify ($2.11). For Protara Therapeutics Inc the two are $0.1920 per share apart. That gap is exactly why we show both numbers side by side.
How much is Protara Therapeutics Inc worth?
The market values Protara Therapeutics Inc at about $140M (market capitalisation, as of Nov 6, 2026). Per share that is $2.30; our models calculate a fair value of $2.11 per share.
What do the bullish and bearish scenarios say about TARA?
Our models span a range for Protara Therapeutics Inc: cautious scenario $1.39, base $2.11, optimistic $2.64 per share (as of Nov 6, 2026, price $2.30). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Protara Therapeutics Inc (TARA)?
Balance-sheet figures for Protara Therapeutics Inc (as of Nov 6, 2026): return on equity −45.8%. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is TARA from its 52-week high?
Protara Therapeutics Inc trades at $2.30, about 70% below its 52-week high of $7.56 and 8% above the low of $2.13 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $2.11 is for.
Which stocks are comparable to Protara Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Protara Therapeutics Inc stock attractive at the current price?
The data as of Nov 6, 2026: price $2.30, calculated fair value $2.11 (−8%), Quality Score 31/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TARA calculated?
We run Protara Therapeutics Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $2.11 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Protara Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Protara Therapeutics Inc (TARA)?
The closing price on Nov 6, 2026 was $2.30. Our model-based fair value is $2.11, about 8% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Protara Therapeutics Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($1.39 to $2.64) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Protara Therapeutics Inc
How large is the market capitalisation of Protara Therapeutics Inc (TARA)?
The market capitalisation of Protara Therapeutics Inc is $140M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Protara Therapeutics Inc (TARA)?
Earnings per share at Protara Therapeutics Inc are $−1.37. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Protara Therapeutics Inc (TARA)?
The return on equity (ROE) of Protara Therapeutics Inc is −45.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Protara Therapeutics Inc (TARA)?
On an EBIT basis the return on assets of Protara Therapeutics Inc is −40.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Protara Therapeutics Inc (TARA) generate?
The free cash flow of Protara Therapeutics Inc is −$56.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Protara Therapeutics Inc (TARA) hold?
Protara Therapeutics Inc holds more cash than debt, $46.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Protara Therapeutics Inc in the live analysis
One click puts Protara Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 6, 2026
